




UNIVERSITAT<sub>DE</sub>  
BARCELONA

## Impact of molecular methods in the analysis of the invasiveness of *Streptococcus pneumoniae*

Eva del Amo Morán



Aquesta tesi doctoral està subjecta a la llicència **Reconeixement- NoComercial 3.0. Espanya de Creative Commons**.

Esta tesis doctoral está sujeta a la licencia **Reconocimiento - NoComercial 3.0. España de Creative Commons**.

This doctoral thesis is licensed under the **Creative Commons Attribution-NonCommercial 3.0. Spain License**.

# **REFERENCES**

## REFERENCES

1. WHO, World Health Organization. Pneumococcal conjugate vaccine for childhood immunization-WHO position paper. *Wkly Epidemiol* 2012;87:129-44.
2. Henriques-Normark B, Tuomanen EI. The pneumococcus: epidemiology, microbiology, and pathogenesis. *Cold Spring Harb Perspect Med* 2013;3(7).
3. Kadioglu A, Weiser JN, Paton JC, Andrew PW. The role of *Streptococcus pneumoniae* virulence factors in host respiratory colonization and disease. *Nat Rev Microbiol* 2008;6(4):288-301.
4. Mitchell AM, Mitchell TJ. *Streptococcus pneumoniae*: virulence factors and variation. *Clin Microbiol Infect* 2010;16(5):411-8.
5. Geno KA, Gilbert GL, Song JY, Skovsted IC, Klugman KP, Jones C, et al. Pneumococcal Capsules and Their Types: Past, Present, and Future. *Clin Microbiol Rev* 2015;28(3):871-99.
6. Hausdorff WP, Bryant J, Paradiso PR, Siber GR. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. *Clin Infect Dis* 2000;30(1):100-21.
7. Brueggemann AB, Griffiths DT, Meats E, Peto T, Crook DW, Spratt BG. Clonal relationships between invasive and carriage *Streptococcus pneumoniae* and serotype- and clone-specific differences in invasive disease potential. *J Infect Dis* 2003;187(9):1424-32.
8. Brueggemann AB, Peto TE, Crook DW, Butler JC, Kristinsson KG, Spratt BG. Temporal and geographic stability of the serogroup-specific invasive disease potential of *Streptococcus pneumoniae* in children. *J Infect Dis* 2004;190(7):1203-11.

9. Sleeman KL, Griffiths D, Shackley F, Diggle L, Gupta S, Maiden MC, et al. Capsular serotype-specific attack rates and duration of carriage of *Streptococcus pneumoniae* in a population of children. *J Infect Dis* 2006;194(5):682-8.
10. Song JY, Nahm MH, Moseley MA. Clinical implications of pneumococcal serotypes: invasive disease potential, clinical presentations, and antibiotic resistance. *J Korean Med Sci* 2013;28(1):4-15.
11. WHO, World Health Organization. Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine among adults aged  $\geq 65$  years: recommendations of the Advisory Committee on Immunization Practices (ACIP)–WHO position paper. *Morbidity and Mortality Wkly Report* 2014;63(37):822-5.
12. Dinleyici EC, Yargic ZA. Pneumococcal conjugated vaccines: impact of PCV-7 and new achievements in the postvaccine era. *Expert Rev Vaccines* 2008;7(9):1367-94.
13. Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, Bennett NM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. *J Infect Dis* 2010;201(1):32-41.
14. von Gottberg A, de Gouveia L, Tempia S, Quan V, Meiring S, von Mollendorf C, et al. Effects of vaccination on invasive pneumococcal disease in South Africa. *N Engl J Med* 2014;371(20):1889-99.
15. Ben-Shimol S, Greenberg D, Givon-Lavi N, Elias N, Glikman D, Rubinstein U, et al. Rapid reduction in invasive pneumococcal disease after introduction of PCV7 into the National Immunization Plan in Israel. *Vaccine* 2012;30(46):6600-7.
16. Choe YJ, Choi EH, Lee HJ. The changing epidemiology of childhood pneumococcal disease in Korea. *Infect Chemother* 2013;45(2):145-58.

17. Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. *Lancet Infect Dis* 2011;11(10):760-8.
18. O'Brien KL, Dagan R. The potential indirect effect of conjugate pneumococcal vaccines. *Vaccine* 2003;21(17-18):1815-25.
19. Hausdorff WP, Siber G, Paradiso PR. Geographical differences in invasive pneumococcal disease rates and serotype frequency in young children. *Lancet* 2001;357(9260):950-2.
20. Hausdorff WP, Feikin DR, Klugman KP. Epidemiological differences among pneumococcal serotypes. *Lancet Infect Dis* 2005;5(2):83-93.
21. Weinberger DM, Malley R, Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. *Lancet* 2011;378(9807):1962-73.
22. Muñoz-Almagro C, Jordan I, Gene A, Latorre C, Garcia-Garcia JJ, Pallares R. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine. *Clin Infect Dis* 2008;46(2):174-82.
23. Singleton RJ, Hennessy TW, Bulkow LR, Hammitt LL, Zulz T, Hurlburt DA, et al. Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. *JAMA* 2007;297(16):1784-92.
24. Pérez-Trallero E, Marimon JM, Ercibengoa M, Vicente D, Pérez-Yarza EG. Invasive *Streptococcus pneumoniae* infections in children and older adults in the north of Spain before and after the introduction of the heptavalent pneumococcal conjugate vaccine. *Eur J Clin Microbiol Infect Dis* 2009;28(7):731-8.

25. Muñoz-Almagro C, Esteva C, de Sevilla MF, Selva L, Gene A, Pallares R. Emergence of invasive pneumococcal disease caused by multidrug-resistant serotype 19A among children in Barcelona. *J Infect* 2009;59(2):75-82.
26. Esteva C, Selva L, de Sevilla MF, Garcia-Garcia JJ, Pallares R, Muñoz-Almagro C. *Streptococcus pneumoniae* serotype 1 causing invasive disease among children in Barcelona over a 20-year period (1989-2008). *Clin Microbiol Infect* 2011;17(9):1441-4.
27. Pelton SI, Huot H, Finkelstein JA, Bishop CJ, Hsu KK, Kellenberg J, et al. Emergence of 19A as virulent and multidrug resistant *Pneumococcus* in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine. *Pediatr Infect Dis J* 2007;26(6):468-72.
28. Hanquet G, Kissling E, Fenoll A, George R, Lepoutre A, Lernout T, et al. Pneumococcal serotypes in children in 4 European countries. *Emerg Infect Dis* 2010;16(9):1428-39.
29. Esposito S, Principi N. Impacts of the 13-valent pneumococcal conjugate vaccine in children. *J Immunol Research* 2015.
30. Demczuk WH, Martin I, Griffith A, Lefebvre B, McGeer A, Lovgren M, et al. Serotype distribution of invasive *Streptococcus pneumoniae* in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine, 2010-2012. *Can J Microbiol* 2013;59(12):778-88.
31. Ben-Shimol S, Greenberg D, Givon-Lavi N, Schlesinger Y, Somekh E, Aviner S, et al. Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: an active prospective nationwide surveillance. *Vaccine* 2014;32(27):3452-9.

32. Harboe ZB, Dalby T, Weinberger DM, Benfield T, Mølbak K, Slotved HC, et al. Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality. *Clin Infect Dis* 2014;59(8):1066-73.
33. Richter SS, Diekema DJ, Heilmann KP, Dohrn CL, Riahi F, Doern GV. Changes in pneumococcal serotypes and antimicrobial resistance after introduction of the 13-valent conjugate vaccine in the United States. *Antimicrob Agents Chemother* 2014;58(11):6484-9.
34. Andrews NJ, Waight PA, Burbidge P, Pearce E, Roalfe L, Zancolli M, et al. Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study. *Lancet Infect Dis* 2014;14(9):839-46.
35. Kellogg JA, Bankert DA, Elder CJ, Gibbs JL, Smith MC. Identification of *Streptococcus pneumoniae* revisited. *J Clin Microbiol* 2001;39(9):3373-5.
36. Blaschke AJ. Interpreting assays for the detection of *Streptococcus pneumoniae*. *Clin Infect Dis* 2011;52 Suppl 4:S331-7.
37. Werno AM, Murdoch DR. Medical microbiology: laboratory diagnosis of invasive pneumococcal disease. *Clin Infect Dis* 2008;46(6):926-32.
38. Johansson N, Kalin M, Tiveljung-Lindell A, Giske CG, Hedlund J. Etiology of community-acquired pneumonia: increased microbiological yield with new diagnostic methods. *Clin Infect Dis* 2010;50(2):202-9.
39. Carvalho MaG, Tondella ML, McCaustland K, Weidlich L, McGee L, Mayer LW, et al. Evaluation and improvement of real-time PCR assays targeting *lytA*, *ply*, and *psaA* genes for detection of pneumococcal DNA. *J Clin Microbiol* 2007;45(8):2460-6.
40. Clements H, Stephenson TJ. Blood culture is poor method of confirming pneumococcus as cause of childhood pneumonia. *BMJ* 1996;313(7059):757.

41. Lahti E, Mertsola J, Kontiokari T, Eerola E, Ruuskanen O, Jalava J. Pneumolysin polymerase chain reaction for diagnosis of pneumococcal pneumonia and empyema in children. *Eur J Clin Microbiol Infect Dis* 2006;25(12):783-9.
42. Van Gastel E, Bruynseels P, Verstrepen W, Mertens A. Evaluation of a real-time polymerase chain reaction assay for the diagnosis of pneumococcal and meningococcal meningitis in a tertiary care hospital. *Eur J Clin Microbiol Infect Dis* 2007;26(9):651-3.
43. Muñoz-Almagro C, Gala S, Selva L, Jordan I, Tarragó D, Pallares R. DNA bacterial load in children and adolescents with pneumococcal pneumonia and empyema. *Eur J Clin Microbiol Infect Dis* 2011;30(3):327-35.
44. Ogami M, Hotomi M, Togawa A, Yamanaka N. A comparison of conventional and molecular microbiology in detecting differences in pneumococcal colonization in healthy children and children with upper respiratory illness. *Eur J Pediatr* 2010;169(10):1221-5.
45. Messmer TO, Sampson JS, Stinson A, Wong B, Carlone GM, Facklam RR. Comparison of four polymerase chain reaction assays for specificity in the identification of *Streptococcus pneumoniae*. *Diagn Microbiol Infect Dis* 2004;49(4):249-54.
46. Clarke SC. Detection of *Neisseria meningitidis*, *Streptococcus pneumoniae*, and *Haemophilus influenzae* in blood and cerebrospinal fluid using fluorescence-based PCR. *Methods Mol Biol* 2006;345:69-77.
47. CDC, Centers for Disease Control and Prevention. Laboratory Methods for the Diagnosis of Meningitis. Chapter 10: PCR for Detection and Characterization of Bacterial Meningitis Pathogens: *Neisseria meningitidis*, *Haemophilus influenzae*, and *Streptococcus pneumoniae* 2014 [updated April 1].
48. Selva L, Ciruela P, Esteva C, de Sevilla MF, Codina G, Hernandez S, et al. Serotype 3 is a common serotype causing invasive pneumococcal disease in children



less than 5 years old, as identified by real-time PCR. *Eur J Clin Microbiol Infect Dis* 2012;31(7):1487-95.

49. Burckhardt I, Roemer J, Burckhardt F, Zimmermann S. Serotyping of pneumococci: evaluation of the genetic approach and performance with clinical samples. *Diagn Microbiol Infect Dis* 2014;80(4):274-7.

50. Austrian R. The quellung reaction, a neglected microbiologic technique. *Mt Sinai J Med* 1976;43(6):699-709.

51. Habib M, Porter BD, Satzke C. Capsular serotyping of *Streptococcus pneumoniae* using the Quellung reaction. *J Vis Exp* 2014(84):e51208.

52. Richter SS, Heilmann KP, Dohrn CL, Riahi F, Diekema DJ, Doern GV. Evaluation of pneumococcal serotyping by multiplex PCR and quellung reactions. *J Clin Microbiol* 2013;51(12):4193-5.

53. Pai R, Gertz RE, Beall B. Sequential multiplex PCR approach for determining capsular serotypes of *Streptococcus pneumoniae* isolates. *J Clin Microbiol* 2006;44(1):124-31.

54. Cieslewicz MJ, Kasper DL, Wang Y, Wessels MR. Functional analysis in type Ia group B *Streptococcus* of a cluster of genes involved in extracellular polysaccharide production by diverse species of streptococci. *J Biol Chem* 2001;276(1):139-46.

55. Bentley SD, Aanensen DM, Mavroidi A, Saunders D, Rabinowitsch E, Collins M, et al. Genetic analysis of the capsular biosynthetic locus from all 90 pneumococcal serotypes. *PLoS Genet* 2006;2(3):e31.

56. Jauneikaite E, Tocheva AS, Jefferies JM, Gladstone RA, Faust SN, Christodoulides M, et al. Current methods for capsular typing of *Streptococcus pneumoniae*. *J Microbiol Methods* 2015;113:41-9.

57. Batt SL, Charalambous BM, McHugh TD, Martin S, Gillespie SH. Novel PCR-restriction fragment length polymorphism method for determining serotypes or serogroups of *Streptococcus pneumoniae* isolates. *J Clin Microbiol* 2005;43(6):2656-61.
58. Selva L, del Amo E, Brotons P, Muñoz-Almagro C. Rapid and easy identification of capsular serotypes of *Streptococcus pneumoniae* by use of fragment analysis by automated fluorescence-based capillary electrophoresis. *J Clin Microbiol* 2012;50(11):3451-7.
59. Massire C, Gertz RE, Svoboda P, Levert K, Reed MS, Pohl J, et al. Concurrent serotyping and genotyping of pneumococci by use of PCR and electrospray ionization mass spectrometry. *J Clin Microbiol* 2012;50(6):2018-25.
60. O'Sullivan MV, Zhou F, Sintchenko V, Kong F, Gilbert GL. Multiplex PCR and reverse line blot hybridization assay (mPCR/RLB). *J Vis Exp* 2011(54).
61. Kong F, Brown M, Sabananthan A, Zeng X, Gilbert GL. Multiplex PCR-based reverse line blot hybridization assay to identify 23 *Streptococcus pneumoniae* polysaccharide vaccine serotypes. *J Clin Microbiol* 2006;44(5):1887-91.
62. Zhou F, Kong F, Tong Z, Gilbert GL. Identification of less-common *Streptococcus pneumoniae* serotypes by a multiplex PCR-based reverse line blot hybridization assay. *J Clin Microbiol* 2007;45(10):3411-5.
63. Tarragó D, Fenoll A, Sánchez-Tatay D, Arroyo LA, Muñoz-Almagro C, Esteva C, et al. Identification of pneumococcal serotypes from culture-negative clinical specimens by novel real-time PCR. *Clin Microbiol Infect* 2008;14(9):828-34.
64. Pimenta FC, Roundtree A, Soysal A, Bakir M, du Plessis M, Wolter N, et al. Sequential triplex real-time PCR assay for detecting 21 pneumococcal capsular serotypes that account for a high global disease burden. *J Clin Microbiol* 2013;51(2):647-52.

65. Bhat S, Herrmann J, Armishaw P, Corbisier P, Emslie KR. Single molecule detection in nanofluidic digital array enables accurate measurement of DNA copy number. *Anal Bioanal Chem* 2009;394(2):457-67.
66. Chan M, Chan MW, Loh TW, Law HY, Yoon CS, Than SS, et al. Evaluation of nanofluidics technology for high-throughput SNP genotyping in a clinical setting. *J Mol Diagn* 2011;13(3):305-12.
67. Dhoubhadel BG, Yasunami M, Yoshida LM, Thi HA, Thi TH, Thi TA, et al. A novel high-throughput method for molecular serotyping and serotype-specific quantification of *Streptococcus pneumoniae* using a nanofluidic real-time PCR system. *J Med Microbiol* 2014;63(Pt 4):528-39.
68. Dhoubhadel BG, Yasunami M, Nguyen HA, Suzuki M, Vu TH, Thi Thuy Nguyen A, et al. Bacterial load of pneumococcal serotypes correlates with their prevalence and multiple serotypes is associated with acute respiratory infections among children less than 5 years of age. *PLoS One* 2014;9(10):e110777.
69. Tomita Y, Okamoto A, Yamada K, Yagi T, Hasegawa Y, Ohta M. A new microarray system to detect *Streptococcus pneumoniae* serotypes. *J Biomed Biotechnol* 2011;2011:352736.
70. Turner P, Hinds J, Turner C, Jankhot A, Gould K, Bentley SD, et al. Improved detection of nasopharyngeal cocolonization by multiple pneumococcal serotypes by use of latex agglutination or molecular serotyping by microarray. *J Clin Microbiol* 2011;49(5):1784-9.
71. Marimon JM, Monasterio A, Ercibengoa M, Pascual J, Prieto I, Simón L, et al. Antibody microarray typing, a novel technique for *Streptococcus pneumoniae* serotyping. *J Microbiol Methods* 2010;80(3):274-80.

72. Leung MH, Bryson K, Freystatter K, Pichon B, Edwards G, Charalambous BM, et al. Sequotyping: serotyping *Streptococcus pneumoniae* by a single PCR sequencing strategy. *J Clin Microbiol* 2012;50(7):2419-27.
73. Liyanapathirana V, Ang I, Tsang D, Fung K, Ng TK, Zhou H, et al. Application of a target enrichment-based next-generation sequencing protocol for identification and sequence-based prediction of pneumococcal serotypes. *BMC Microbiol* 2014;14:60.
74. Siira L, Kaijalainen T, Lambertsen L, Nahm MH, Toropainen M, Virolainen A. From Quellung to multiplex PCR, and back when needed, in pneumococcal serotyping. *J Clin Microbiol* 2012;50(8):2727-31.
75. Bello Gonzalez T, Rivera-Olivero IA, Sisco MC, Spadola E, Hermans PW, de Waard JH. PCR deduction of invasive and colonizing pneumococcal serotypes from Venezuela: a critical appraisal. *J Infect Dev Ctries* 2014;8(4):469-73.
76. Bogaert D, De Groot R, Hermans PW. *Streptococcus pneumoniae* colonisation: the key to pneumococcal disease. *Lancet Infect Dis* 2004;4(3):144-54.
77. Brugger SD, Frey P, Aebi S, Hinds J, Mühlemann K. Multiple colonization with *S. pneumoniae* before and after introduction of the seven-valent conjugated pneumococcal polysaccharide vaccine. *PLoS One* 2010;5(7):e11638.
78. Kalsoft MS, Skov Sørensen UB, Slotved HC, Konradsen HB. An easy method for detection of nasopharyngeal carriage of multiple *Streptococcus pneumoniae* serotypes. *J Microbiol Methods* 2008;75(3):540-4.
79. Donkor ES, Bishop CJ, Gould K, Hinds J, Antonio M, Wren B, et al. High levels of recombination among *Streptococcus pneumoniae* isolates from the Gambia. *MBio* 2011;2(3):e00040-11.

80. Kamng'ona AW, Hinds J, Bar-Zeev N, Gould KA, Chaguza C, Msefula C, et al. High multiple carriage and emergence of *Streptococcus pneumoniae* vaccine serotype variants in Malawian children. *BMC Infect Dis* 2015;15:234.
81. Bronsdon MA, O'Brien KL, Facklam RR, Whitney CG, Schwartz B, Carlone GM. Immunoblot method to detect *Streptococcus pneumoniae* and identify multiple serotypes from nasopharyngeal secretions. *J Clin Microbiol* 2004;42(4):1596-600.
82. da Gloria Carvalho M, Pimenta FC, Jackson D, Roundtree A, Ahmad Y, Millar EV, et al. Revisiting pneumococcal carriage by use of broth enrichment and PCR techniques for enhanced detection of carriage and serotypes. *J Clin Microbiol* 2010;48(5):1611-8.
83. Pimenta FC, Carvalho MaG, Gertz RE, Bastos-Rocha CG, Oliveira LS, Lacerda Pigosso L, et al. Serotype and genotype distributions of pneumococcal carriage isolates recovered from Brazilian children attending day-care centres. *J Med Microbiol* 2011;60(Pt 10):1455-9.
84. Rivera-Olivero IA, Blommaart M, Bogaert D, Hermans PW, de Waard JH. Multiplex PCR reveals a high rate of nasopharyngeal pneumococcal 7-valent conjugate vaccine serotypes co-colonizing indigenous Warao children in Venezuela. *J Med Microbiol* 2009;58(Pt 5):584-7.
85. Browall S, Norman M, Tångrot J, Galanis I, Sjöström K, Dagerhamn J, et al. Intracloal variations among *Streptococcus pneumoniae* isolates influence the likelihood of invasive disease in children. *J Infect Dis* 2014;209(3):377-88.
86. Blomberg C, Dagerhamn J, Dahlberg S, Browall S, Fernebro J, Albiger B, et al. Pattern of accessory regions and invasive disease potential in *Streptococcus pneumoniae*. *J Infect Dis* 2009;199(7):1032-42.

87. Henriques-Normark B, Blomberg C, Dagerhamn J, Bättig P, Normark S. The rise and fall of bacterial clones: *Streptococcus pneumoniae*. *Nat Rev Microbiol* 2008;6(11):827-37.
88. Robinson DA, Edwards KM, Waites KB, Briles DE, Crain MJ, Hollingshead SK. Clones of *Streptococcus pneumoniae* isolated from nasopharyngeal carriage and invasive disease in young children in central Tennessee. *J Infect Dis* 2001;183(10):1501-7.
89. Sandgren A, Sjostrom K, Olsson-Liljequist B, Christensson B, Samuelsson A, Kronvall G, et al. Effect of clonal and serotype-specific properties on the invasive capacity of *Streptococcus pneumoniae*. *J Infect Dis* 2004;189(5):785-96.
90. Sjöström K, Spindler C, Ortqvist A, Kalin M, Sandgren A, Kühlmann-Berenzon S, et al. Clonal and capsular types decide whether pneumococci will act as a primary or opportunistic pathogen. *Clin Infect Dis* 2006;42(4):451-9.
91. Hiller NL, Ahmed A, Powell E, Martin DP, Eutsey R, Earl J, et al. Generation of genic diversity among *Streptococcus pneumoniae* strains via horizontal gene transfer during a chronic polyclonal pediatric infection. *PLoS Pathog* 2010;6(9):e1001108.
92. Enright MC, Spratt BG. A multilocus sequence typing scheme for *Streptococcus pneumoniae*: identification of clones associated with serious invasive disease. *Microbiology* 1998;144 ( Pt 11):3049-60.
93. Donkor ES, Adegbola RA, Wren BW, Antonio M. Population biology of *Streptococcus pneumoniae* in West Africa: multilocus sequence typing of serotypes that exhibit different predisposition to invasive disease and carriage. *PLoS One* 2013;8(1):e53925.

94. Obert CA, Gao G, Sublett J, Tuomanen EI, Orihuela CJ. Assessment of molecular typing methods to determine invasiveness and to differentiate clones of *Streptococcus pneumoniae*. *Infect Genet Evol* 2007;7(6):708-16.
95. Grundmann H, Hori S, Tanner G. Determining confidence intervals when measuring genetic diversity and the discriminatory abilities of typing methods for microorganisms. *J Clin Microbiol* 2001;39(11):4190-2.
96. Corless CE, Guiver M, Borrow R, Edwards-Jones V, Fox AJ, Kaczmarek EB. Simultaneous detection of *Neisseria meningitidis*, *Haemophilus influenzae*, and *Streptococcus pneumoniae* in suspected cases of meningitis and septicemia using real-time PCR. *J Clin Microbiol* 2001;39(4):1553-8.
97. Obando I, Muñoz-Almagro C, Arroyo LA, Tarrago D, Sanchez-Tatay D, Moreno-Perez D, et al. Pediatric parapneumonic empyema, Spain. *Emerg Infect Dis* 2008;14(9):1390-7.
98. Saha SK, Darmstadt GL, Baqui AH, Hossain B, Islam M, Foster D, et al. Identification of serotype in culture negative pneumococcal meningitis using sequential multiplex PCR: implication for surveillance and vaccine design. *PLoS One* 2008;3(10):e3576.
99. Eltringham G, Kearns A, Freeman R, Clark J, Spencer D, Eastham K, et al. Culture-negative childhood empyema is usually due to penicillin-sensitive *Streptococcus pneumoniae* capsular serotype 1. *J Clin Microbiol* 2003;41(1):521-2.
100. Huebner RE, Dagan R, Porath N, Wasas AD, Klugman KP. Lack of utility of serotyping multiple colonies for detection of simultaneous nasopharyngeal carriage of different pneumococcal serotypes. *Pediatr Infect Dis J* 2000;19(10):1017-20.

101. Saha S, Modak JK, Naziat H, Al-Emran HM, Chowdury M, Islam M, et al. Detection of co-colonization with *Streptococcus pneumoniae* by algorithmic use of conventional and molecular methods. *Vaccine* 2015;33(5):713-8.
102. Ebruke C, Roca A, Egere U, Darboe O, Hill PC, Greenwood B, et al. Temporal changes in nasopharyngeal carriage of *Streptococcus pneumoniae* serotype 1 genotypes in healthy Gambians before and after the 7-valent pneumococcal conjugate vaccine. *PeerJ* 2015;3:e903.
103. Nunes S, Sá-Leão R, Pereira LC, de Lencastre H. Emergence of a serotype 1 *Streptococcus pneumoniae* lineage colonising healthy children in Portugal in the seven-valent conjugate vaccination era. *Clin Microbiol Infect* 2008;14(1):82-4.
104. Jourdain S, Drèze PA, Verhaegen J, Van Melderen L, Smeesters PR. Carriage-associated *Streptococcus pneumoniae* serotype 1 in Brussels, Belgium. *Pediatr Infect Dis J* 2013;32(1):86-7.
105. Smith-Vaughan H, Marsh R, Mackenzie G, Fisher J, Morris PS, Hare K, et al. Age-specific cluster of cases of serotype 1 *Streptococcus pneumoniae* carriage in remote indigenous communities in Australia. *Clin Vaccine Immunol* 2009;16(2):218-21.
106. Aguiar SI, Brito MJ, Gonçalo-Marques J, Melo-Cristino J, Ramirez M. Serotypes 1, 7F and 19A became the leading causes of pediatric invasive pneumococcal infections in Portugal after 7 years of heptavalent conjugate vaccine use. *Vaccine* 2010;28(32):5167-73.
107. Imöhl M, Reinert RR, van der Linden M. Temporal Variations among Invasive Pneumococcal Disease Serotypes in Children and Adults in Germany (1992-2008). *Int J Microbiol* 2010;2010:874189.



108. Meichtry J, Born R, Küffer M, Zwahlen M, Albrich WC, Brugger SD, et al. Serotype epidemiology of invasive pneumococcal disease in Swiss adults: a nationwide population-based study. *Vaccine* 2014;32(40):5185-91.
109. Byington CL, Samore MH, Stoddard GJ, Barlow S, Daly J, Korgenski K, et al. Temporal trends of invasive disease due to *Streptococcus pneumoniae* among children in the intermountain west: emergence of nonvaccine serogroups. *Clin Infect Dis* 2005;41(1):21-9.
110. Hanage WP, Kaijalainen TH, Syrjänen RK, Auranen K, Leinonen M, Mäkelä PH, et al. Invasiveness of serotypes and clones of *Streptococcus pneumoniae* among children in Finland. *Infect Immun* 2005;73(1):431-5.
111. Shouval DS, Greenberg D, Givon-Lavi N, Porat N, Dagan R. Site-specific disease potential of individual *Streptococcus pneumoniae* serotypes in pediatric invasive disease, acute otitis media and acute conjunctivitis. *Pediatr Infect Dis J* 2006;25(7):602-7.
112. Kronenberg A, Zucs P, Droz S, Mühlemann K. Distribution and invasiveness of *Streptococcus pneumoniae* serotypes in Switzerland, a country with low antibiotic selection pressure, from 2001 to 2004. *J Clin Microbiol* 2006;44(6):2032-8.
113. Sá-Leão R, Pinto F, Aguiar S, Nunes S, Carriço JA, Frazão N, et al. Analysis of invasiveness of pneumococcal serotypes and clones circulating in Portugal before widespread use of conjugate vaccines reveals heterogeneous behavior of clones expressing the same serotype. *J Clin Microbiol* 2011;49(4):1369-75.
114. Rivera-Olivero IA, del Nogal B, Sisco MC, Bogaert D, Hermans PW, de Waard JH. Carriage and invasive isolates of *Streptococcus pneumoniae* in Caracas, Venezuela: the relative invasiveness of serotypes and vaccine coverage. *Eur J Clin Microbiol Infect Dis* 2011;30(12):1489-95.

115. Inverarity D, Diggle M, Ure R, Santana-Hernandez D, Altstadt P, Mitchell T, et al. Simultaneous nasopharyngeal carriage of two pneumococcal multilocus sequence types with a serotype 3 phenotype. *Int J Microbiol* 2010;2010:765479.
116. Martens P, Worm SW, Lundgren B, Konradsen HB, Benfield T. Serotype-specific mortality from invasive *Streptococcus pneumoniae* disease revisited. *BMC Infect Dis* 2004;4:21.
117. Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Lexau C, Bennett NM, et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance *Lancet Infect Dis*. 2015;15(3):301-9.
118. van der Linden M, Falkenhorst G, Perniciaro S, Imöhl M. Effects of Infant Pneumococcal Conjugate Vaccination on Serotype Distribution in Invasive Pneumococcal Disease among Children and Adults in Germany. *PLoS One* 2015;10(7):e0131494.
119. Lepoutre A, Varon E, Georges S, Dorléans F, Janoir C, Gutmann L, et al. Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012. *Vaccine* 2015;33(2):359-66.
120. García Gabarrot G, López Vega M, Pérez Giffoni G, Hernández S, Cardinal P, Félix V, et al. Effect of pneumococcal conjugate vaccination in Uruguay, a middle-income country. *PLoS One* 2014;9(11):e112337.
121. Regev-Yochay G, Paran Y, Bishara J, Oren I, Chowers M, Tziba Y, et al. Early impact of PCV7/PCV13 sequential introduction to the national pediatric immunization plan, on adult invasive pneumococcal disease: A nationwide surveillance study. *Vaccine* 2015;33(9):1135-42.

122. Lee GM, Kleinman K, Pelton SI, Hanage W, Huang SS, Lakoma M, et al. Impact of 13-Valent Pneumococcal Conjugate Vaccination on Streptococcus pneumoniae Carriage in Young Children in Massachusetts. *J Pediatric Infect Dis Soc* 2014;3(1):23-32.
123. Gounder PP, Bruce MG, Bruden DJ, Singleton RJ, Rudolph K, Hurlburt DA, et al. Effect of the 13-valent pneumococcal conjugate vaccine on nasopharyngeal colonization by Streptococcus pneumoniae--Alaska, 2008-2012. *J Infect Dis* 2014;209(8):1251-8.
124. Hanage WP, Fraser C, Tang J, Connor TR, Corander J. Hyper-recombination, diversity, and antibiotic resistance in pneumococcus. *Science* 2009;324(5933):1454-7.
125. Yildirim I, Hanage WP, Lipsitch M, Shea KM, Stevenson A, Finkelstein J, et al. Serotype specific invasive capacity and persistent reduction in invasive pneumococcal disease. *Vaccine* 2010;29(2):283-8.
126. Melin M, Trzciński K, Meri S, Käyhty H, Väkeväinen M. The capsular serotype of Streptococcus pneumoniae is more important than the genetic background for resistance to complement. *Infect Immun* 2010;78(12):5262-70.
127. Kelly T, Dillard JP, Yother J. Effect of genetic switching of capsular type on virulence of Streptococcus pneumoniae. *Infect Immun* 1994;62(5):1813-9.
128. Garau J, Calbo E. Capsular types and predicting patient outcomes in pneumococcal bacteremia. *Clin Infect Dis* 2007;45(1):52-4.
129. Willems RJ, Hanage WP, Bessen DE, Feil EJ. Population biology of Gram-positive pathogens: high-risk clones for dissemination of antibiotic resistance. *FEMS Microbiol Rev* 2011;35(5):872-900.

130. Beall BW, Gertz RE, Hulkower RL, Whitney CG, Moore MR, Brueggemann AB. Shifting genetic structure of invasive serotype 19A pneumococci in the United States. *J Infect Dis* 2011;203(10):1360-8.
131. Choi EH, Kim SH, Eun BW, Kim SJ, Kim NH, Lee J, et al. Streptococcus pneumoniae serotype 19A in children, South Korea. *Emerg Infect Dis* 2008;14(2):275-81.
132. Moore MR, Gertz RE, Woodbury RL, Barkocy-Gallagher GA, Schaffner W, Lexau C, et al. Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. *J Infect Dis* 2008;197(7):1016-27.
133. Ardanuy C, Rolo D, Fenoll A, Tarrago D, Calatayud L, Liñares J. Emergence of a multidrug-resistant clone (ST320) among invasive serotype 19A pneumococci in Spain. *J Antimicrob Chemother* 2009;64(3):507-10.
134. Chang Q, Stevenson AE, Croucher NJ, Lee GM, Pelton SI, Lipsitch M, et al. Stability of the pneumococcal population structure in Massachusetts as PCV13 was introduced. *BMC Infect Dis* 2015;15:68.
135. Brueggemann AB, Spratt BG. Geographic distribution and clonal diversity of Streptococcus pneumoniae serotype 1 isolates. *J Clin Microbiol* 2003;41(11):4966-70.
136. Gonzalez BE, Hulten KG, Kaplan SL, Mason EO, Group UPMPSS. Clonality of Streptococcus pneumoniae serotype 1 isolates from pediatric patients in the United States. *J Clin Microbiol* 2004;42(6):2810-2.
137. Ardanuy C, Tubau F, Pallares R, Calatayud L, Domínguez MA, Rolo D, et al. Epidemiology of invasive pneumococcal disease among adult patients in barcelona before and after pediatric 7-valent pneumococcal conjugate vaccine introduction, 1997-2007. *Clin Infect Dis* 2009;48(1):57-64.

138. Johnson HL, Deloria-Knoll M, Levine OS, Stoszek SK, Freimanis Hance L, Reithinger R, et al. Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. *PLoS Med* 2010;7(10).
139. Beall B, McEllistrem MC, Gertz RE, Wedel S, Boxrud DJ, Gonzalez AL, et al. Pre- and postvaccination clonal compositions of invasive pneumococcal serotypes for isolates collected in the United States in 1999, 2001, and 2002. *J Clin Microbiol* 2006;44(3):999-1017.
140. Henriques B, Kalin M, Ortqvist A, Olsson Liljequist B, Almela M, Marrie TJ, et al. Molecular epidemiology of *Streptococcus pneumoniae* causing invasive disease in 5 countries. *J Infect Dis* 2000;182(3):833-9.
141. Louie M, Louie L, Papia G, Talbot J, Lovgren M, Simor AE. Molecular analysis of the genetic variation among penicillin-susceptible and penicillin-resistant *Streptococcus pneumoniae* serotypes in Canada. *J Infect Dis* 1999;179(4):892-900.
142. Overweg K, Bogaert D, Sluijter M, Yother J, Dankert J, de Groot R, et al. Genetic relatedness within serotypes of penicillin-susceptible *Streptococcus pneumoniae* isolates. *J Clin Microbiol* 2000;38(12):4548-53.
143. Jauneikaite E, Mary Carnon Jefferies J, William Vere Churton N, Tzer Pin Lin R, Lloyd Hibberd M, Charles Clarke S. Genetic diversity of *Streptococcus pneumoniae* causing meningitis and sepsis in Singapore during the first year of PCV7 implementation. *Emerg Microbes Infect* 2014;3(6):e39.
144. Jefferies JM, Smith A, Clarke SC, Dowson C, Mitchell TJ. Genetic analysis of diverse disease-causing pneumococci indicates high levels of diversity within serotypes and capsule switching. *J Clin Microbiol* 2004;42(12):5681-8.

145. Isozumi R, Ito Y, Ishida T, Hirai T, Ito I, Maniwa K, et al. Molecular characteristics of serotype 3 *Streptococcus pneumoniae* isolates among community-acquired pneumonia patients in Japan. *J Infect Chemother* 2008;14(3):258-61.
146. Feikin DR, Klugman KP. Historical changes in pneumococcal serogroup distribution: implications for the era of pneumococcal conjugate vaccines. *Clin Infect Dis* 2002;35(5):547-55.
147. Inverarity DJ, Diggle MA. Observations regarding historical accounts of pneumococcal diseases due to serotypes 1 and 3. *J R Coll Physicians Edinb* 2010;40(4):354-61.
148. Selva L, Ciruela P, Blanchette K, del Amo E, Pallares R, Orihuela CJ, et al. Prevalence and clonal distribution of *pcpA*, *psrP* and *Pilus-1* among pediatric isolates of *Streptococcus pneumoniae* *PLoS One* 2012;7(7):e41587.
149. Barocchi MA, Ries J, Zogaj X, Hemsley C, Albiger B, Kanth A, et al. A pneumococcal pilus influences virulence and host inflammatory responses. *Proc Natl Acad Sci U S A* 2006;103(8):2857-62.
150. Sjöström K, Blomberg C, Fernebro J, Dagerhamn J, Morfeldt E, Barocchi MA, et al. Clonal success of piliated penicillin nonsusceptible pneumococci. *Proc Natl Acad Sci U S A* 2007;104(31):12907-12.
151. Sadowy E, Kuch A, Gniadkowski M, Hryniewicz W. Expansion and evolution of the *Streptococcus pneumoniae* Spain9V-ST156 clonal complex in Poland. *Antimicrob Agents Chemother* 2010;54(5):1720-7.
152. Caierão J, Hawkins P, Sant'anna FH, da Cunha GR, d'Azevedo PA, McGee L, et al. Serotypes and genotypes of invasive *Streptococcus pneumoniae* before and after PCV10 implementation in southern Brazil. *PLoS One* 2014;9(10):e111129.

153. Regev-Yochay G, Hanage WP, Trzcinski K, Rifas-Shiman SL, Lee G, Bessolo A, et al. Re-emergence of the type 1 pilus among *Streptococcus pneumoniae* isolates in Massachusetts, USA. *Vaccine* 2010;28(30):4842-6.
154. Wyres KL, Lambertsen LM, Croucher NJ, McGee L, von Gottberg A, Liñares J, et al. Pneumococcal capsular switching: a historical perspective. *J Infect Dis* 2013;207(3):439-49.
155. Varon E, Cohen R, Béchet S, Doit C, Levy C. Invasive disease potential of pneumococci before and after the 13-valent pneumococcal conjugate vaccine implementation in children. *Vaccine* 2015;33(46):6178-85.
156. Zulz T, Wenger JD, Rudolph K, Robinson DA, Rakov AV, Bruden D, et al. Molecular characterization of *Streptococcus pneumoniae* serotype 12F isolates associated with rural community outbreaks in Alaska. *J Clin Microbiol* 2013;51(5):1402-7.
157. Schillberg E, Isaac M, Deng X, Peirano G, Wylie JL, Van Caesele P, et al. Outbreak of invasive *Streptococcus pneumoniae* serotype 12F among a marginalized inner-city population in Winnipeg, Canada, 2009-2011. *Clin Infect Dis* 2014;59(5):651-7.
158. Robinson DA, Turner JS, Facklam RR, Parkinson AJ, Breiman RF, Gratten M, et al. Molecular characterization of a globally distributed lineage of serotype 12F *Streptococcus pneumoniae* causing invasive disease. *J Infect Dis* 1999;179(2):414-22.
159. Antonio M, Dada-Adegbola H, Biney E, Awine T, O'Callaghan J, Pfluger V, et al. Molecular epidemiology of pneumococci obtained from Gambian children aged 2-29 months with invasive pneumococcal disease during a trial of a 9-valent pneumococcal conjugate vaccine. *BMC Infect Dis* 2008;8:81.

160. Pantosti A, Gherardi G, Conte M, Faella F, Dicuonzo G, Beall B. A novel, multiple drug-resistant, serotype 24F strain of *Streptococcus pneumoniae* that caused meningitis in patients in Naples, Italy. *Clin Infect Dis* 2002;35(2):205-8.
161. Gherardi G, D'Ambrosio F, Visaggio D, Dicuonzo G, Del Grosso M, Pantosti A. Serotype and clonal evolution of penicillin-nonsusceptible invasive *Streptococcus pneumoniae* in the 7-valent pneumococcal conjugate vaccine era in Italy. *Antimicrob Agents Chemother* 2012;56(9):4965-8.
162. Ardanuy C, Marimón JM, Calatayud L, Giménez M, Alonso M, Grau I, et al. Epidemiology of invasive pneumococcal disease in older people in Spain (2007-2009): implications for future vaccination strategies. *PLoS One* 2012;7(8):e43619.
163. Setchanova LP, Alexandrova A, Dacheva D, Mitov I, Kaneva R, Mitev V. Dominance of multidrug-resistant Denmark(14)-32 (ST230) clone among *Streptococcus pneumoniae* serotype 19A isolates causing pneumococcal disease in Bulgaria from 1992 to 2013. *Microb Drug Resist* 2015;21(1):35-42.
164. Aguiar SI, Pinto FR, Nunes S, Serrano I, Melo-Cristino J, Sá-Leão R, et al. Denmark14-230 clone as an increasing cause of pneumococcal infection in Portugal within a background of diverse serotype 19A lineages. *J Clin Microbiol* 2010;48(1):101-8.
165. Steens A, Bergsaker MA, Aaberge IS, Rønning K, Vestrheim DF. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway. *Vaccine* 2013;31(52):6232-8.
166. Golden AR, Adam HJ, Gilmour MW, Baxter MR, Martin I, Nichol KA, et al. Assessment of multidrug resistance, clonality and virulence in non-PCV-13



*Streptococcus pneumoniae* serotypes in Canada, 2011-13. *J Antimicrob Chemother* 2015;70(7):1960-4.

167. Pichon B, Ladhani SN, Slack MP, Segonds-Pichon A, Andrews NJ, Waight PA, et al. Changes in molecular epidemiology of *streptococcus pneumoniae* causing meningitis following introduction of pneumococcal conjugate vaccination in England and Wales. *J Clin Microbiol* 2013;51(3):820-7.

168. Birtles A, McCarthy N, Sheppard CL, Rutter H, Guiver M, Haworth E, et al. Multilocus sequence typing directly on DNA from clinical samples and a cultured isolate to investigate linked fatal pneumococcal disease in residents of a shelter for homeless men. *J Clin Microbiol* 2005;43(4):2004-8.

169. Jefferies JM, Johnston CH, Kirkham LA, Cowan GJ, Ross KS, Smith A, et al. Presence of nonhemolytic pneumolysin in serotypes of *Streptococcus pneumoniae* associated with disease outbreaks. *J Infect Dis* 2007;196(6):936-44.